With more than 100 years of scientific expertise and a presence in over 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”
Cyagen Biomodels LLC
Founded in 2006, Cyagen is a global provider of genetically modified rodent models and advanced CRO solutions for biomedical research and drug development. With more than 900 employees and research facilities covering 40,000 m², Cyagen supports researchers in over 100 countries and has contributed to more than 13,000 peer-reviewed publications, including in Cell, Nature, and Science. Headquartered in Santa Clara, California, Cyagen also operates subsidiaries in Japan and China, with major R&D and production centers in Guangzhou, Suzhou, and Gu’an. Combining expertise in cell and animal model generation with AI-driven discovery platforms, Cyagen provides scalable, reliable, one-stop solutions for basic research and preclinical drug development. Cyagen has developed several proprietary platforms to advance translational research, including HUGO-GT™ genomic humanized mouse models, the Rare Disease Data Center (RDDC) integrating genetic databases and AI tools
Curia Global, Inc
Curia is a global Contract Development and Manufacturing Organization with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing to make treatments broadly accessible to patients. We offer services across Small Molecules, Generic APIs, and Biologics backed by deep scientific expertise and a robust global network of resources and capabilities. Our dedicated teams, combined with advanced technologies, enable us to be both flexible and scalable, accelerating the delivery of your product to patients. From curiosity to cure, we are your trusted ally, delivering every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com | Curia is a global CDMO with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing. Our Biologics services span discovery to clinical manufacturing, including clinical and commercial fill-finish services, for antibodies, recombinant proteins, mRNA therapeutics and many large molecule products. Curia’s expertise and agility deliver a best-in-class experience across discovery, drug substance and drug product development and manufacturing. From curiosity to cure, we are your trusted ally to accelerate life-changing therapeutics. To learn more, visit us at https://curiaglobal.com/biologics/
CuraScript SD by Evernorth
CuraScript SD provides integrated delivery solutions for the safe & efficient distribution of specialty pharmaceuticals & associated medical supplies. We’ve been caring for those who care for more than a quarter of a century by supplying biologics, branded drugs, generics, vaccines, infused medications and ancillary supportive care products to a wide range of medical providers.
Cumberland Pharmaceuticals
Focus on underserved niche markets, including hospital acute care and gastroenterology, we supply products that offer distinct advantages over prior treatments. Our commitment to excellence propels us on our mission of providing innovative products that address poorly met medical needs.
CryoCrate
CryoCrate is an NIH Innovation Showcase company advancing next-generation tissue cryopreservation and tissue engineering technologies, supported by 12 NIH and DoD awards. The company has developed a first-in-class biocompatible preservation platform based on proprietary nano ice formation and glycocalyx-mediated mechanisms. Unlike conventional approaches, CryoCrate’s polysaccharide-based formulation is free of small-molecule permeating cryoprotectants, enabling preservation without compromising structural integrity or cellular function. This platform supports cryopreservation of ocular tissues, particularly corneal grafts, as well as skin and a wide range of cell types for transplantation and clinical biobanking. In parallel, its glycocalyx-targeted approach enhances wound healing and supports tissue engineering applications, positioning CryoCrate at the intersection of regenerative medicine and transplantation.
CorMedix Therapeutics
Melinta Therapeutics provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes seven commercial-stage products. With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information. | At CorMedix Therapeutics, we’re driven to protect vulnerable patients from serious, life-threatening infections. With eight commercial-stage products spanning prevention and treatment, we address critical, unmet needs across multiple care settings. Our dedicated team is committed to ensuring access to our therapies and to continuously expanding our portfolio to improve patient outcomes. Discover more at www.cormedix.com
Colgate Oral Pharmaceuticals
Colgate-Palmolive is the global leader in oral care technology, products, and education. Colgate s products include technologically advanced toothpastes, toothbrushes, mouth rinses, and floss. Our Colgate Oral Pharmaceuticals subsidiary provides professional fluoride, gingival health, and tooth whitening products. Please visit our booth for additional information and an overview of our complete line of professional products.
Colgate-Palmolive Canada
Colgate-Palmolive is the global leader in Oral Care Technology, products and education. Colgate’s products include technologically advanced toothpastes, toothbrushes, mouth rinses and floss. Visit our booth for additional information and an overview of our complete line of professional products. Smile first, and let your confidence do the talking!
Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting bacterial biofilms. The Columbus, Ohio-based company is building a pipeline of immune-enabling medicines, including CMTX-101, which completed a positive Phase 2 study in cystic fibrosis patients in early 2026, and plans to pursue additional mid-stage studies in other chronic respiratory diseases including bronchiectasis. The company’s second program, CMTX-301, is in early development to evaluate the technology in a preventive approach. | Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory disease decline through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2a study for infections associated with cystic fibrosis, and CMTX-301, an anti-biofilm vaccine in early development.